Deramiocel (CAP-1002)

Name: Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Current treatment options and standard of care
Published: 2026-09-14T15:39:06-04:00

Duchenne muscular dystrophy

Manufacturer: Capricor Therapeutics
Regulatory submission: Class 2 BLA resubmission submitted February 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Current treatment options and standard of care

15 evidence topics · 8 sources

Corticosteroids2 evidence topics · 2 sources
Gene replacement therapy2 evidence topics · 1 source
Exon-skipping antisense oligonucleotides1 evidence topic · 1 source
Histone deacetylase inhibitors2 evidence topics · 1 source
Physical and occupational therapy1 evidence topic · 1 source
Cardioprotective therapies1 evidence topic · 2 sources
Respiratory support1 evidence topic · 1 source
Bone health therapies1 evidence topic · 1 source
Nutritional support1 evidence topic · 1 source
Psychosocial support1 evidence topic · 1 source
Limitations of current therapies2 evidence topics · 5 sources